Pliant Therapeutics, Inc. - PLRX STOCK NEWS

Pliant Therapeutics (Nasdaq: PLRX) announced the presentation of two scientific posters at the International Liver Congress™ 2022 in London from June 22-26, 2022. The posters will focus on the dual inhibition of integrins α_vß₆ and α_vß₁ by PLN-74809 in treating primary sclerosing cholangitis (PSC).

The first poster highlights findings from preclinical studies, while the second investigates portal pressure and liver fibrosis in rats with biliary cirrhosis. The presentations will be available on-demand at Pliant's website.

Pliant Therapeutics (Nasdaq: PLRX) presented five scientific posters at the 2022 American Thoracic Society International Conference in San Francisco from May 13-18, 2022. The data showcased their lead product, PLN-74809, a dual-selective inhibitor aimed at treating idiopathic pulmonary fibrosis (IPF). Key findings included safety data indicating PLN-74809 was well-tolerated in over 450 subjects, with no severe adverse events. Interim results from Phase 2a trials demonstrated dose-dependent target engagement in IPF patients, reinforcing the therapeutic potential of PLN-74809.

Pliant Therapeutics (Nasdaq: PLRX), a clinical-stage biotechnology firm, announced that its President and CEO, Bernard Coulie, will participate in two investor conferences in May 2022. The RBC Capital Markets Global Healthcare conference will feature a fireside chat on May 18 at 10:00 a.m. ET, while a replay of the H.C. Wainwright Global Investment Conference chat will be available on May 23 at 7:00 a.m. ET. Interested parties can access these events on Pliant's Investor Relations page.

Pliant Therapeutics (Nasdaq: PLRX) provided a corporate update on May 9, 2022, announcing a $100 million loan facility from Oxford Finance that extends its cash runway to mid-2024. The company is advancing its clinical programs, notably the INTEGRIS-IPF Phase 2a trial for PLN-74809, expected to yield data in mid-2022. The drug received FDA Fast Track and EMA Orphan Drug designations for treating idiopathic pulmonary fibrosis and primary sclerosing cholangitis. Financially, R&D and G&A expenses increased, resulting in a net loss of $28.1 million for Q1 2022.

Pliant Therapeutics, a clinical-stage biotechnology company, has secured a loan facility of up to $100 million from Oxford Finance LLC. This non-dilutive financing is aimed at advancing its lead clinical candidate, PLN-74809, for treating idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The funding will extend Pliant's cash runway to mid-2024, supporting multiple upcoming clinical milestones. An initial draw of $10 million has been made, with further funds available based on performance milestones.

Pliant Therapeutics (NASDAQ: PLRX) announced that its drug candidate, PLN-74809, has received Fast Track designation from the FDA for treating idiopathic pulmonary fibrosis (IPF). This designation highlights the urgent need for new treatments for this severe disease, which affects approximately 140,000 people annually in the U.S. PLN-74809, currently in a Phase 2a clinical trial (INTEGRIS-IPF), aims to address the high unmet medical need as existing therapies do not halt disease progression. Topline data from the trial is expected in mid-2022.

Pliant Therapeutics (Nasdaq: PLRX) is presenting five posters at the ATS 2022 International Conference from May 13-18 in San Francisco. The posters showcase data supporting the development of PLN-74809, a dual-selective inhibitor for idiopathic pulmonary fibrosis (IPF). Key findings include dose-dependent target engagement and a favorable safety profile. Pliant is also featured in a special presentation during the ATS Respiratory Innovation Summit. PLN-74809 is currently in Phase 2 trials and has received Orphan Drug Designation from the FDA for IPF and primary sclerosing cholangitis.

Pliant Therapeutics (Nasdaq: PLRX), a clinical-stage biotechnology company, will have its CEO, Bernard Coulie, participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 2:15 p.m. ET. The event can be accessed via the Investor Relations’ Events & Presentation page on Pliant’s website, with an audio archive available for 30 days. Pliant focuses on developing therapies for fibrosis, with its lead candidate, PLN-74809, targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis, having received Orphan Drug Designation from the FDA.

Pliant Therapeutics, Inc. (Nasdaq: PLRX) recently corrected its financial reporting for 2021, highlighting significant advancements in its pipeline. The company reported a net loss of $24.5 million for Q4 2021, up from $19 million in the previous year. R&D expenses increased to $18.8 million, while G&A expenses rose to $7.8 million. PLN-74809, its lead therapeutic candidate, demonstrated robust biological activity in a Phase 1b trial and is poised for further trials in idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company has $200.6 million in cash, sufficient to fund operations into H2 2023.